Victoria Johnson

Verismo plans to begin enrollment in the STAR-101 trial in the first quarter of 2023.

The FDA previously lifted its clinical hold of the AFFINE study in May 2022.

The company previously presented positive preclinical data at the 2021 ASGCT meeting.

Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.

The FDA has cleared the investigational new drug application for AB-201.

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

The FDA authorized the natural killer cell therapy combo for compassionate use.

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.

BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.

iECURE is planning to submit an IND for GTP-506 in mid-2023.

Postmortem analyses revealed cell survival and GDNF production in transplanted areas.

Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.

The FDA has requested additional preclinical data from Beam Therapeutics on BEAM-201.

The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.

The company has filed a patent for the new approach, which is designed to combat T-cell exhaustion.

Lomecel-B is being evaluated in the phase 2 ELPISII study in children with hypoplastic left heart syndrome.

Updated data from the STAAR clinical trial were presented at the SSIEM Annual Meeting.

Researchers used novel functional MRI approaches to better measure the effects of gene therapy in children in current clinical trials.

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

Century Therapeutics will initiate the phase 1 ELiPSE-1 study imminently.

BioMarin plans to resubmit the biologics license application for val-rox to the FDA by the end of September 2022.

iECURE and the University of Pennsylvania Gene Therapy Program have collaborated to develop the GTP-506 program.

Merit Cudkowicz, MD, discussed corrected data from a phase 3 trial of NurOwn that BrainStorm believes supports a BLA submission.

If approved, the company will initiate the first-in-human STAR-101 phase 1 clinical trial.

The company recently announced a dose escalation in the ACCLAIM-1 study.

The pheEDIT clinical trial initiated in June 2022.

ZYNTEGLO is now the world's most expensive gene therapy at a $2.8 million price tag.

Tessa Therapeutics presented positive data from the phase 2 CHARIOT study of TT11 in December 2021.